Italian Sarcoma Group   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: San Lazzaro di Savena Italy (1997)

Organization Overview

First Clinical Trial
2001
NCT00685828
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Italian Sarcoma Group

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Neoplasms (Phase 1)

Chondrosarcoma (Phase 2)

Chondrosarcoma, Mesenchymal (Phase 2)

Fibromatosis, Aggressive (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Leiomyosarcoma (Phase 3)

Liposarcoma (Phase 3)

Liposarcoma, Myxoid (Phase 2)

Neoplasms, Fibrous Tissue (Phase 2)

Osteosarcoma (Phase 3)

Sarcoma (Phase 3)

Sarcoma, Clear Cell (Phase 2)

Sarcoma, Ewing (Phase 3)

Sarcoma, Synovial (Phase 3)

Soft Tissue Neoplasms (Phase 2)

Solitary Fibrous Tumors (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 26